ITI Pharma & Healthcare Growth Direct Plan
SIP amount
Min. ₹500
Lumpsum amount
Min. ₹5,000

ITI Pharma & Healthcare Growth Direct Plan

NAV
₹17.1674
-1.15%
(8 Aug)
AUM
230 Cr
TER
0.47%
Risk
Very High Risk
Insights
Total Expense Ratio (TER) is in the bottom 25% of comparable funds
Net Asset Value (NAV) is below its 200 days moving average
In beta. Send feedback here.
Compare with other fund
1Y
+2.8%
+2.8%
-1.4%
-7.9%
-8.2%
3Y
+31.6%
+22.0%
+31.4%
+33.8%
+33.6%
5Y
+30.3%
NA
+35.3%
+31.1%
+29.4%
ALL
+18.2%
+15.5%
+13.0%
+11.8%
+16.8%
VOL
16.3%
13.7%
21.1%
20.3%
19.8%
TER
0.5%
0.5%
1.1%
0.8%
0.9%
AUM
₹7,200 Cr
₹230 Cr
₹2,591 Cr
₹5,278 Cr
₹1,439 Cr
INFO
1.12
1.13
0.61
0.58
0.85
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
ITI Pharma & Healthcare (G)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 30th Jun
Top holdings
Sun Pharmaceuticals Industries Ltd
12.0%
Divi's Laboratories Ltd
9.0%
Max Healthcare Institute Ltd Ordinary Shares
6.1%
Apollo Hospitals Enterprise Ltd
5.4%
Lupin Ltd
5.1%
Cohance Lifesciences Ltd
4.5%
Torrent Pharmaceuticals Ltd
4.0%
Aurobindo Pharma Ltd
3.7%
Aster DM Healthcare Ltd Ordinary Shares
3.2%
Wockhardt Ltd
2.9%
Top industry exposure
Healthcare
92.0%
Basic Materials
4.2%
Industrials
1.0%
Other information
Minimum SIP
₹500
Minimum lumpsum
₹5,000
Additional lumpsum
₹1,000
Portfolio turnover
57%
Lock-in period
-
Exit load
• 0.5% for redemption within 90 days
Fund objective
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Fund manager(s)
Dhimant Shah
Rohan Korde

FAQs